Market revenue in 2023 | USD 15.0 million |
Market revenue in 2030 | USD 77.9 million |
Growth rate | 26.6% (CAGR from 2023 to 2030) |
Largest segment | Symptomatic treatment |
Fastest growing segment | Symptomatic Treatment |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Symptomatic Treatment |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to huntingtons disease treatment market will help companies and investors design strategic landscapes.
Symptomatic treatment was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Germany huntingtons disease treatment market based on symptomatic treatment covering the revenue growth of each sub-segment from 2018 to 2030.
The Huntington’s disease treatment market in Germany is expected to witness significant growth over the forecast period owing to high burden of the disease, availability of symptom management products, and expected entry of potential disease modifying therapies in the market. Huntexil (pridopidine), which is developed by Prilenia Therapeutics B.V., is expected to enter Germany Huntington’s disease treatment market in 2026.
According to Institute for Applied Health Research Berlin, the period prevalence of HD was reported to be around 9.3 per 100,000 of the population. In addition, the article suggests that around 66.9% patients receive antipsychotics that cost USD 640 per year, out of which Tiapride was prescribed to around 46.8% of HD patients.
Moreover, antidepressants were prescribed to around 45.1% patients, with USD 141.43 annual cost per patient. The most prescribed antidepressant was mirtazapine, accounting for 20.5% of HD patients. However, these drugs do not cure the disease but are used for symptom management in patients.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany huntingtons disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Germany huntingtons disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account